Literature DB >> 15591827

Banking of the human heart valves and the arteries at the European homograft bank (EHB)--overview of a 14-year activity in this International Association in Brussels.

R Jashari1, B Van Hoeck, M Tabaku, A Vanderkelen.   

Abstract

Processing of the human heart valves and arteries has been carried out at the European Homograft Bank (EHB) in Brussels since 1989 and 1991, respectively. Heart valve donors of 0-65 years were classified in (1) Beating heart donors (BHD), of which recipients of heart transplantation (RHT) and multiorgan donors (MOD) after brain death, and (2) non-beating heart donors (NBHD) with warm ischaemic time (WIT) of less then 6 h. Past history of the donors has been checked for malignant and chronic diseases, as well as biology for transmissible and infectious diseases. Perfect collaboration has been established with the transplant coordinators and transplant teams of the implanting centres. Dissection, decontamination, cryopreservation and storing in fluid nitrogen has been carried out in accordance with the Belgian and European Standards of cardiovascular allografts. During this period, a total of 2.828 hearts, 28 predissected valves and 616 batches of arteries arrived in the EHB. 3.537 valves and 1.137 different arteries were accepted for implantation. The main reasons for tissue rejection were morphology, contamination and cuts during the tissue retrieval or dissection. A huge network of different hospitals in Belgium and elsewhere in Europe and Switzerland were included in this process. Pulmonary allografts were not sent for implantation in the left ventricular outflow tract after 1998, since the early and mid-term results after 76 implantations were disappointing. The number of implanted aortic and pulmonary allografts remains stable from year to year, however the number of the allografts used for Ross operation is still increasing. Since the results of the follow up were disappointing, we still only require the implantation and immediate postoperative results, whereas the follow-up information only for specific study purposes.

Entities:  

Mesh:

Year:  2004        PMID: 15591827     DOI: 10.1007/s10561-004-1441-0

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  4 in total

1.  Determination of Residual Antibiotics in Cryopreserved Heart Valve Allografts.

Authors:  Ramadan Jashari; Françoise Faucon; Beatrice Van Hoeck; Seppe De Gelas; Yedong Fan; Stephane Vandenbulcke
Journal:  Transfus Med Hemother       Date:  2011-11-14       Impact factor: 3.747

2.  Profile of Heart Donors from the Human Valve Bank of the Santa Casa de Misericórdia de Curitiba.

Authors:  Renata Maria Ferreira; Marise Teresinha Brenner Affonso da Costa; Osiris Canciglieri Junior; Ângelo Márcio Oliveira Sant'Anna
Journal:  Braz J Cardiovasc Surg       Date:  2016-04

3.  Ten-year experience with cryopreserved vascular allografts in the Croatian Cardiovascular Tissue Bank.

Authors:  M Golemovic; M Skific; D Haluzan; P Pavic; B Golubic Cepulic
Journal:  Cell Tissue Bank       Date:  2022-02-07       Impact factor: 1.522

4.  The risk of transmission of the novel coronavirus (SARS-CoV-2) with human heart valve transplantation: evaluation of cardio-vascular tissues from two consecutive heart donors with asymptomatic COVID-19.

Authors:  R Jashari; M Van Esbroeck; J Vanhaebost; I Micalessi; A Kerschen; S Mastrobuoni
Journal:  Cell Tissue Bank       Date:  2021-03-09       Impact factor: 1.522

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.